232 related articles for article (PubMed ID: 16414331)
1. Estrogen with and without progestin: benefits and risks of short-term use.
LaCroix AZ
Am J Med; 2005 Dec; 118 Suppl 12B():79-87. PubMed ID: 16414331
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the risks and benefits of hormone replacement therapy regimens.
Warren MP
Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
[TBL] [Abstract][Full Text] [Related]
4. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
5. Menopause and stroke and the effects of hormonal therapy.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
7. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
Banks E; Canfell K
Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
[TBL] [Abstract][Full Text] [Related]
8. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
9. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
10. On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause.
Langer RD
Climacteric; 2010 Aug; 13(4):303-6. PubMed ID: 20540591
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).
Robinson JG; Wallace R; Limacher M; Ren H; Cochrane B; Wassertheil-Smoller S; Ockene JK; Blanchette PL; Ko MG
Am J Cardiol; 2008 Sep; 102(6):693-9. PubMed ID: 18773990
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
[TBL] [Abstract][Full Text] [Related]
13. KEEPS: The Kronos Early Estrogen Prevention Study.
Harman SM; Brinton EA; Cedars M; Lobo R; Manson JE; Merriam GR; Miller VM; Naftolin F; Santoro N
Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
[TBL] [Abstract][Full Text] [Related]
14. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.
Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML
Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946
[TBL] [Abstract][Full Text] [Related]
15. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
Obstet Gynecol; 2008 Nov; 112(5):1189-92. PubMed ID: 18978127
[TBL] [Abstract][Full Text] [Related]
16. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
Shapiro S
Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
[TBL] [Abstract][Full Text] [Related]
17. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
Brinton RD
Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
[TBL] [Abstract][Full Text] [Related]
18. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?
Manson JE; Bassuk SS
Am J Epidemiol; 2007 Sep; 166(5):511-7. PubMed ID: 17646204
[TBL] [Abstract][Full Text] [Related]
19. Venous thrombosis and conjugated equine estrogen in women without a uterus.
Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR
Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815
[TBL] [Abstract][Full Text] [Related]
20. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
